Ipsen doubles down on rare musculoskeletal disease via Blueprint deal

Ipsen redoubled its commitment to developing treatments for fibrodysplasia ossificans progressiva by obtaining rights to an ALK2 inhibitor from Blueprint.

The

Read the full 207 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE